Symbicort is a prescription medication and one cannot legally just buy Symbicort online in the US. As a result, Symbicort is also not available over-the-counter. However, with a valid Symbicort prescription, one can get any necessary Symbicort inhalers. Push Health can connect people who need a Symbicort prescription with a licensed medical provider who can prescribe Symbicort medication, including a generic Symbicort inhaler and Symbicort 160/4.5, when appropriate to do so.
While Symbicort is frequently prescribed, it is not a cheap medication. For many people, Symbicort will be moderately expensive at approximately $3 per inhalation at most pharmacies. In some cases, insurance will cover some or all of the cost of a Symbicort prescription. Symbicort coupons are available at times online or from the manufacturer.
Dr. Jill Seladi-Schulman is currently a freelance medical writer and was previously a project setup manager for clinical trials. She specializes in microbiology and infectious disease, having written her dissertation on influenza virus morphology. Dr. Seladi-Schulman has publications in peer-reviewed journals. She also has had her work featured on the cover of the Journal of Virology.
Before taking Symbicort, talk with your doctor and pharmacist. Tell them about all prescription, over-the-counter, and other drugs you take. Also tell them about any vitamins, herbs, and supplements you use. Sharing this information can help you avoid potential interactions.
Your insurance plan may require you to get prior authorization before they approve coverage for Symbicort. This means that your doctor will need to send a request to your insurance company asking them to cover the drug. The insurance company will review the request and let you and your doctor know if your plan will cover Symbicort.
Disclaimer: Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Each strength is supplied as apressurized aluminum canister with an attached counting device, a red plasticactuator body with a white mouthpiece, and attached gray dust cap. Each 120inhalation canister has a net fill weight of 10.2 grams and each 60 inhalationcanister has a net fill weight of 6.9 grams (SYMBICORT 80/4.5) or 6 grams(SYMBICORT 160/4.5). Each canister is packaged in a foil overwrap pouch withdesiccant sachet and placed into a carton. Each carton contains one canisterand a Patient Information leaflet.
The overall safety data in adults and adolescents arebased upon 10 active-and placebo-controlled clinical trials in which 3393patients ages 12 years and older (2052 females and 1341 males) with asthma ofvarying severity were treated with SYMBICORT 80/4.5 or 160/4.5 taken 2inhalations once or twice daily for 12 to 52 weeks. In these trials, thepatients on SYMBICORT had a mean age of 38 years and were predominantlyCaucasian (82%).
As with other inhaled drugs containing beta2-adrenergicagents, SYMBICORT should not be used more often than recommended, at higherdoses than recommended, or in conjunction with other medications containingLABA, as an overdose may result. Clinically significant cardiovascular effectsand fatalities have been reported in association with excessive use of inhaledsympathomimetic drugs. Patients using SYMBICORT should not use an additionalLABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate) for anyreason, including prevention of exercise-induced bronchospasm (EIB) or thetreatment of asthma or COPD.
Physicians should remain vigilant for the possibledevelopment of pneumonia in patients with COPD as the clinical features ofpneumonia and exacerbations frequently overlap. Lower respiratory tractinfections, including pneumonia, have been reported following the inhaledadministration of corticosteroids.
Particular care is needed for patients who have beentransferred from systemically active corticosteroids to inhaled corticosteroidsbecause deaths due to adrenal insufficiency have occurred in patients withasthma during and after transfer from systemic corticosteroids to lesssystemically available inhaled corticosteroids. After withdrawal from systemiccorticosteroids, a number of months are required for recovery ofhypothalamic-pituitary-adrenal (HPA) function.
It is possible that systemic corticosteroid effects suchas hypercorticism and adrenal suppression (including adrenal crisis) may appearin a small number of patients, particularly when budesonide is administered athigher than recommended doses over prolonged periods of time. If such effectsoccur, the dosage of SYMBICORT should be reduced slowly, consistent withaccepted procedures for reducing systemic corticosteroids and for management ofasthma symptoms.
Effects of treatment with SYMBICORT 160/4.5, SYMBICORT80/4.5, formoterol 4.5 mcg, or placebo on BMD was evaluated in a subset of 326patients (females and males 41 to 88 years of age) with COPD in the 12-monthlung function study. BMD evaluations of the hip and lumbar spine regions wereconducted at baseline and 52 weeks using dual energy x-ray absorptiometry (DEXA)scans. Mean changes in BMD from baseline to end of treatment were small (meanchanges ranged from -0.01 -0.01 g/cm²). ANCOVA results for total spine andtotal hip BMD based on the end of treatment time point showed that allgeometric LS Mean ratios for the pairwise treatment group comparisons wereclose to 1, indicating that overall, BMD for total hip and total spine regionsfor the 12-month time point were stable over the entire treatment period.
Studies of pregnant women have not shown that inhaledbudesonide increases the risk of abnormalities when administered duringpregnancy. The results from a large population-based prospective cohort epidemiologicalstudy reviewing data from three Swedish registries covering approximately 99%of the pregnancies from 1995-1997 (i.e., Swedish Medical Birth Registry;Registry of Congenital Malformations; Child Cardiology Registry) indicate noincreased risk for congenital malformations from the use of inhaled budesonideduring early pregnancy. Congenital malformations were studied in 2014 infantsborn to mothers reporting the use of inhaled budesonide for asthma in earlypregnancy (usually 10-12 weeks after the last menstrual period), the periodwhen most major organ malformations occur. The rate of recorded congenitalmalformations was similar compared to the general population rate (3.8% vs.3.5%, respectively). In addition, after exposure to inhaled budesonide, thenumber of infants born with orofacial clefts was similar to the expected numberin the normal population (4 children vs. 3.3, respectively).
In a study of asthmatic children 5 to 12 years of age,those treated with budesonide DPI 200 mcg twice daily (n=311) had a 1.1centimeter reduction in growth compared with those receiving placebo (n=418) atthe end of one year; the difference between these two treatment groups did notincrease further over three years of additional treatment. By the end of 4years, children treated with budesonide DPI and children treated with placebohad similar growth velocities. Conclusions drawn from this study may beconfounded by the unequal use of corticosteroids in the treatment groups andinclusion of data from patients attaining puberty during the course of thestudy.
In the COPD studies of 6 to 12 months duration, 810patients treated with SYMBICORT 160/4.5, two inhalations twice daily were 65years old and above and of those, 177 patients were 75 years of age and older.No overall differences in safety or effectiveness were observed between thesepatients and younger patients, and other reported clinical experience has notidentified differences in responses between the elderly and younger patients.
SYMBICORT contains both budesonide and formoterol;therefore, the risks associated with overdosage for the individual componentsdescribed below apply to SYMBICORT. In pharmacokinetic studies, single doses of960/54 mcg (12 actuations of SYMBICORT 80/4.5) and 1280/36 mcg (8 actuations of160/4.5), were administered to patients with COPD. A total of 1920/54 mcg (12actuations of SYMBICORT 160/4.5) was administered as a single dose to bothhealthy subjects and patients with asthma. In a long-term active-controlledsafety study in adolescent and adult asthma patients 12 years of age and older,SYMBICORT 160/4.5 was administered for up to 12 months at doses up to twice thehighest recommended daily dose. There were no clinically significant adversereactions observed in any of these studies.
The potential for acute toxic effects following overdoseof budesonide is low. If used at excessive doses for prolonged periods,systemic corticosteroid effects such as hypercorticism may occur [see WARNINGSAND PRECAUTIONS]. Budesonide at five times the highest recommended dose(3200 mcg daily) administered to humans for 6 weeks caused a significantreduction (27%) in the plasma cortisol response to a 6-hour infusion of ACTHcompared with placebo (+1%). The corresponding effect of 10 mg prednisone dailywas a 35% reduction in the plasma cortisol response to ACTH. 781b155fdc